Nervous Disorder TRIZ Cases

Lower oral doses distributed over multiple daily administrations treat MDD while limiting peak esketamine exposure and mutagenicity risk.

GM37var2 binds the 112–117 alpha-synuclein epitope and multiple aggregate forms, addressing limited coverage in early MSA treatment.

Acetobacteriaceae compositions use bacterial enzymes and metabolites to raise ATP production and activate mitochondrial biogenesis.

Abnormal AMPA calcium permeability can inhibit NMDA signaling; an antagonist such as perampanel helps restore receptor function.

Selective G-protein signaling in MOR agonists preserves pain relief while limiting β-arrestin recruitment, tolerance, and opioid side effects.

Retrograde-enhanced clade E AAV capsids deliver RNAi to RVM neurons to reduce CamKv activity in chronic pain pathways.

Small molecules, oligonucleotides, and antibodies inhibit FLI-1 to reduce pericyte loss, BBB breakdown, and Aβ deposition in Alzheimer’s models.

Current RIP1 inhibitors lack broad effectiveness; oral bicyclic ketone compounds selectively suppress RIP1 activity linked to inflammation and necroptosis.

Antibodies and secretion inhibitors target circulating aP2 to reduce insulin resistance and improve glucose metabolism.

Isoprenoid compounds restore mevalonate pathway output and protein prenylation while reducing statin-related cytotoxicity and other adverse effects.

Blocking L1 endonuclease activity limits retrotransposition, DNA damage, and proinflammatory signaling linked to aging.

Azido-labeled extracellular vesicles bind hydrogel microparticles through click chemistry to deliver therapeutic components for brain repair after stroke.

Existing anti-tau antibodies may bind tau broadly; this case uses configured CDRs to recognize p-tau 217 for earlier AD detection.

CHF6467 combines intranasal mutant NGF with mild hypothermia to reduce infarct volume and neuroinflammation without hyperalgesia.

Omomyc inhibits Myc activity, reduces splenocyte proliferation, and delays autoimmune disease onset with minimal dosing.

Anti-CCR4 therapy can have limited effect after neuronal destruction; RGMa inhibition addresses inflammation and neuronal cell death in HAM.

This case uses rAAV vectors and targeted promoters to raise cerebrospinal-fluid PGRN and address neurological lysosomal disease symptoms.

The case addresses limited multi-symptom treatment by using lisuride to improve social behavior and pre-pulse suppression in animal models.

An RGMa-inhibiting agent targets the pathway behind abnormal protein aggregate accumulation and supports neuronal health.

Short Tau peptides are weak immunogens; carrier-coupled phosphorylated fragments are designed to elicit high-titer antibodies against tauopathy.

Purified psilocybin derivatives, terpenes, and cannabinoids address slow onset and side effects through controlled composite dosing.

Forming ZnCl2 co-crystals improves blarcamesine hydrochloride stability and solubility while supporting uniform pharmaceutical dosage processing.

Current treatments can miss diverse pain etiologies; adjustable cyclic peptide derivatives are developed to treat or prevent neuropathic and inflammatory pain.

Treatment-resistant seizures and persistent nocturnal snoring are addressed with highly purified CBD used alongside anti-epileptic drugs in Doose Syndrome.

Humanizing anti-Tau(pS422) antibodies helps balance blood-brain barrier penetration with selective binding to pathological Tau.

Stable expression of CsCCD2L, CsUGT2, and CsUGT709G1 in tomato and potato bypasses labor-intensive saffron harvesting for crocin production.

Nicotine replacement can cause irritation and recurrence; muscarinic antagonists reduce withdrawal symptoms through receptor blockade.

Specific heteroatom placement in azaindole compounds tunes CDK8/CDK19 binding to address broad kinase activity and off-target effects.

JCV-binding antibodies inhibit viral attachment and replication, offering a prophylactic and therapeutic approach to PML in immunocompromised patients.

Limited TRK treatment specificity for mutations and fusions is addressed with bivalent compounds that recruit E3 ligases for targeted protein degradation.

Cyclodextrin inclusion complexes improve oral allopregnanolone absorption and bioavailability, supporting at-home CNS treatment.

CRL-activating compounds use molecular-glue or PROTAC behavior to ubiquitinate and degrade proteins lacking conventional binding pockets.

Hydrophilic excipients and crospovidone enable rapid saliva-driven disintegration while preserving tablet hardness, stability, and therapeutic concentration.

Lipid nanoparticles deliver modified mRNA into the cytoplasm, avoiding DNA integration while shortening protein-expression lag in difficult cell types.

Small molecules activate PKC and stabilize E-cadherin, helping embryonic stem cells survive trypsin passaging and retain phenotype.

Macrocyclization and substituent changes target mutant and wild-type TRK while addressing limited activity and pharmacokinetic performance.

An acidic black soybean seed coat extract targets stress-related autonomic imbalance while supporting cognitive function and fatigue relief.

Antibodies bind alpha-synuclein monomers and fibrils to inhibit aggregation and block toxic spread between neurons.

Subanesthetic ketamine targets NMDA receptors to provide rapid PTSD symptom relief while limiting effects associated with anesthetic doses.

Defined XRPD patterns characterize crystalline tryptamine derivatives, improving molecular weight accuracy for pharmaceutical dosing.

Biphenyl-linked pyrrolidine sulfonamides address the need for new orexin type 2 agonists to support narcolepsy treatment.

A glycine, saccharide, and buffer liquid stabilizes isolated mitochondria while helping prevent platelet aggregation and blood clot formation during injection.

Therapeutic peptides block ATAD3A–Drp1 binding to limit mitochondrial fragmentation and mtDNA lesions in Huntington’s disease models.

Low-dose IL-2 can reduce Tfr cells; pairing it with an IL-1 inhibitor supports Treg development and broader immune control.

Novel small-molecule USP7 inhibitors address poor selectivity while supporting immune activation, CD8+ T-cell infiltration, and antitumor efficacy.

Targeting SARM1 with substituted pyridine compounds aims to halt axonal degeneration and preserve neuronal connectivity.

Current CLN3-Batten treatments do not slow disease progression; rAAV9 delivers functional CLN3 to neuronal cells for gene-level intervention.

Age-related inflammation linked to L1 activity is addressed with selective endonuclease inhibitors that reduce retrotransposition and SASP.

Pairing bortezomib or carfilzomib with a Formula I compound creates synergistic treatment aimed at limiting cancer drug resistance.

CD98hc-targeted antigen-binding domains facilitate BBB transport to improve CNS delivery while limiting peripheral exposure.